Homepage
Author:
Amplia Therapuetics Limited
Posted Date:
March 23, 2026
Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial
Amplia Therapuetics Limited
March 23, 2026
Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
Amplia Therapuetics Limited
March 9, 2026
Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial
Amplia Therapuetics Limited
February 12, 2026
Amplia Therapeutics – Quarterly Activities and Cash Flow Reports – December 2025
Amplia Therapuetics Limited
January 30, 2026
NARMAFOTINIB Large-Scale Manufactre Complete
Amplia Therapuetics Limited
January 27, 2026